Recent Advances in the Management of Adverse Events Associated with Lorlatinib

被引：1
|
作者：
Liao, Dehua [1 ]
Zhang, Jiwen [1 ,2 ]
Yan, Ting [1 ]
Chen, Shanshan [1 ]
Li, Wei [1 ]
Shangguan, Dangang [1 ]
She, Zhihua [3 ]
机构：
[1] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Pharm, Changsha, Peoples R China
[2] Univ South China, Sch Pharm, Hengyang, Peoples R China
[3] Hunan Prov Maternal & Child Hlth Care Hosp, Dept Med Adm, Changsha, Peoples R China
来源：
ONCOTARGETS AND THERAPY | 2023年 / 16卷
关键词：
ALK; lorlatinib; adverse event; NSCLC; therapy management; CELL LUNG-CANCER; ALK; INHIBITOR; EFFICACY; SAFETY; PENETRANT; ROS1;
D O I：
10.2147/OTT.S426989
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on firstand second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.
引用
收藏
页码：731 / 738
页数：8
相关论文
共 50 条
  • [41] Adverse Events Associated with Clevidipine
    Karydes, H. C.
    Leikin, J. B.
    [J]. CLINICAL TOXICOLOGY, 2010, 48 (06) : 663 - 663
  • [42] Association between the adverse events and serum concentrations of lorlatinib in patients with advanced ALKpositive lung cancer
    Shimoda, Y.
    Yoshida, T.
    Makihara, R. A.
    Torasawa, M.
    Tateishi, A.
    Matsumoto, Y.
    Shinno, Y.
    Okuma, Y.
    Goto, Y.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [43] Adverse drug reactions and pharmacogenomics: recent advances
    Alfirevic, Ana
    Pirmohamed, Munir
    [J]. PERSONALIZED MEDICINE, 2008, 5 (01) : 11 - 23
  • [44] Recent advances in the management of intestinal failure-associated liver disease
    Wiles, Alan
    Woodward, Jeremy M.
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2009, 12 (03): : 265 - 272
  • [45] Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis
    Misra, Durga Prasanna
    Naidu, G. S. R. S. N. K.
    Sharma, Aman
    [J]. INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (03) : 218 - 228
  • [46] RECENT ADVANCES IN PREVENTION, DIAGNOSIS AND MANAGEMENT OF DEMENTIA AND THE ASSOCIATED NEUROPSYCHIATRIC SYMPTOMS
    Ismail, Zahinoor
    Rajji, Tarek K.
    Kumar, Sanjeev
    Burhan, Amer
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 25 (03): : S33 - S33
  • [47] Recent Advances in Stroke Management
    Diener, H. C.
    [J]. CEREBROVASCULAR DISEASES, 2015, 40 : 5 - 5
  • [48] RECENT ADVANCES IN MANAGEMENT OF CML
    Shah, Binay
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6162 - 6162
  • [49] RECENT ADVANCES IN MANAGEMENT OF BURNS
    MUNSTER, AM
    PRUITT, BA
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1971, 1 (09) : 484 - &
  • [50] Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
    Solomon, B. J.
    Mok, T. S. K.
    Hayashi, H.
    Bearz, A.
    Penkov, K. D.
    Wu, Y-L.
    Arrieta, O.
    Calella, A. M.
    Peltz, G.
    Polli, A.
    Thurm, H.
    Bauer, T. M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S957 - S958
12345